Screening for coronary artery disease in type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1434-1442

  Upchurch, Charles T ^a   Barrett, Eugene J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN; TROPONIN T;

ANGIOPLASTY; ATHEROSCLEROSIS; CARDIAC IMAGING; CARDIOVASCULAR RISK; COMORBIDITY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TOLERANCE; HEART EJECTION FRACTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; MYOCARDIAL PERFUSION IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS ECHOCARDIOGRAPHY; SURVIVAL RATE; CORONARY ARTERY BYPASS GRAFT; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; RISK FACTORS;

EID: 84860772990     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2122     Document Type: Review

References (72)

1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinico RF, Bales VS, Marks JS 2003 Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:76-79
2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB 1998 Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847
3. National Diabetes Information Clearinghouse 2008 Diabetes overview. NIH Publication 09-3873. Bethesda, MD: National Institutes of Health
4. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR 1987 Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59:750-755
5. Libb YP, Nathan DM, Abraha MK, Brunzell JD, Fradkin JE, Haffner SM, Hsue HW, Rewer SM, Roberts BT, Savage PJ, Skarlato SS, Wassef M, Rabadan-Diehl C 2005 Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111:3489-3493
6. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith Jr SC, Sowers JR 1999 Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100:1134-1146
7. Rutter MK, McComb JM, Brady S, Marshall SM 1999 Silent myocardial ischemia and microalbuminuria in asymptomatic subjects with non-insulin- dependent diabetes mellitus. Am J Cardiol 83:27-31
8. Langer A, Freeman MR, Josse RG, Steiner G, Armstrong PW 1991 Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 67:1073-1078
9. Nak AM, Hiramats UK, Aizaw AT, Momos EA, Yoshizawa K, Shigematsu S, Ishihara F, Niwa A, Yamada T 1992 Silent myocardial ischemia inpatients with non-insulin-dependent diabetes mellitus as judged by treadmill exercise testing and coronary angiography. Am Heart J 123:46-53
10. Rutter MK, Wahid ST, McComb JM, Marshall SM 2002 Significance of silent ischemia and microalbuminuria in predicting coronary events in a symptomatic patients with type2diabetes. J Am Coll Cardiol 40:56-61
11. Miller TD, Rajagopalan N, Hodge DO, Frye RL, Gibbons RJ 2004 Yield of stress single-photon emission computed tomography in asymptomatic patients with diabetes. Am Heart J 147:890-896
12. Cosso NE, Nguyen MT, Chan UB, Ban UI, Chihe BS, Balt AC, Takbou K, Valensi P 2011 Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients. Diabetes Care 34:2101-2107
13. Tsujimoto T, Kajio H, Takahashi Y, Kishimoto M, Noto H, Yamamoto-Honda R, Kamimura M, Morooka M, Kubota K, Shimbo T, Hiroe M, Noda M 2011 Asymptomatic coronary heart disease in patients with type 2 diabetes with vascular complications: a cross-sectional study. BMJ Open 1:e000139
14. Rajagopalan N, Miller TD, Hodge DO, Frye RL, Gibbons RJ 2005 Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol 45:43-49
15. Sorajj AP, Chareonthaitawee P, Rajagopalan N, Miller TD, Frye RL, Hodge DO, Gibbons RJ 2005 Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. Circulation 112:I311-I316
16. 2011 Standards of medical care in diabetes-2011. Diabetes Care 34(Suppl 1):S11-S61
17. 2006 Standards of medical care in diabetes-2006. Diabetes Care 29(Suppl 1):S4-S42
18. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ 2007 Screening for coronary artery disease in patients with diabetes. Diabetes Care 30:2729-2736
19. Valensi P, Cosson E 2010 It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. Diabetes Metab 36:91-96
20. Shah PK 2010 Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J Am Coll Cardiol 56:98-105
21. Hendel RC, Budoff MJ, Cardella JF, Chambers CE, Dent JM, Fitzgerald DM, Hodgson JM, Klodas E, Kramer CM, Stillman AE, Tilkemeier PL, Ward RP, Weigold WG, White RD, Woodard PK 2009 ACC/AHA/ACR/ASE/ASNC/HRS/NASCI/RSNA/SAIP/SCAI/ SCCT/SCMR/SIR 2008 Key data elements and definitions for cardiac imaging: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Cardiac Imaging). J Am Coll Cardiol 53:91-124
22. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith Jr SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK 2010 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 122:e584-e636
23. Ferket BS, Genders TS, Colkesen EB, Visser JJ, Spronk S, Steyerberg EW, Hunink MG 2011 Systematic review of guidelines on imaging of asymptomatic coronary artery disease. J Am Coll Cardiol 57:1591-1600
24. Coleman RL, Stevens RJ, Retnakaran R, Holman RR 2007 Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 30:1292-1293
25. van der Heijden AA, Ortegon MM, Niessen LW, Nijpels G, Dekker JM 2009 Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: the Hoorn Study. Diabetes Care 32:2094-2098
26. Bansal S, Wackers FJ, Inzucchi SE, Chyun DA, Davey JA, Staib LH, Young LH 2011 Five-year outcomes in high-risk participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study: a post hoc analysis. Diabetes Care 34:204-209
27. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE 2005 Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipidmeasures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294:326-333
28. de Lemos JA, Drazner MH, Omlan DT, Ayers CR, Kher AA, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK 2010 Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304:2503-2512
29. de Filippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL 2010 Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 304:2494-2502
30. Hallén J, Johansen OE, Birkeland KI, Gullestad L, Aakhus S, Endresen K, Tjora S, Jaffe AS, Atar D 2010 Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus. Cardiovasc Diabetol 9:52
31. Ashley EA, Myers J, Froelicher V 2000 Exercise testing in clinical medicine. Lancet 356:1592-1597
32. Lauer M, Froelicher ES, Williams M, Kligfield P 2005 Exercise testing in asymptomatic adults: a statement for professionals from the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 112:771-776
33. Cosson E, Paycha F, Paries J, Cattan S, Ramadan A, Meddah D, Attali JR, Valensi P 2004 Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintigraphy? Diabet Med 21:342-348
34. Rubler S, Gerber D, Reitano J, Chokshi V, Fisher VJ 1987 Predictive value of clinical and exercise variables for detection of coronary artery diseasein men with diabetes mellitus. Am J Cardiol 59:1310-1313
35. Vanzetto G, Halimi S, Hammoud T, Fagret D, Benhamou PY, Cordonnie RD, Deni SB, Machecourt J 1999 Prediction of cardio vascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care 22:19-26
36. Zellweger MJ, Hachamovitch R, Kang X, Hayes SW, Friedman JD, German OG, Pfisterer ME, Berman DS 2004 Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. Eur Heart J 25:543-550
37. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE 2009 Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes. The DIAD study: a randomized controlled trial. JAMA 301:1547-1555
38. Scholte AJ, Bax JJ, Wackers FJ 2006 Screening of asymptomatic patients with type 2 diabetes mellitus for silent coronary artery disease: combined use of stress myocardial perfusion imaging and coronary calcium scoring. J Nucl Cardiol 13:11-18
39. Heller GV 2005 Evaluation of the patient with diabetes mellitus and suspected coronary artery disease. Am J Med 118(Suppl 2):9S-14S
40. Scognamigli OR, Negut C, Ramondo A, Tiengo A, Avogaro A 2006 Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 47:65-71
41. Jacquemine TS, Barthelem YO, Rouze TF, Isnar DR, Halbro NM, Bouzamondo A, Le Guludec D, Grimaldi A, Metzger JP, Le Feuvre C 2010 Arandomizedstu dy comparing is otope and echocardiography stress testing in the screening of silent myocardial ischaemia in type 2 diabetic patients. Diabetes Metab 36:463-469
42. Penfornis A, Zimmermann C, Boumal D, Sabbah A, Meneveau N, Gaultier-Bourgeois S, Bassand JP, Bernard Y 2001 Use of dobutamine stress echocardiography in detecting silent myocardial ischaemia in asymptomatic diabetic patients: a comparison with thallium scintigraphy and exercise testing. Diabet Med 18:900-905
43. Raggi P, Shaw LJ, Berman DS, Callister TQ 2004 Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 43:1663-1669
44. Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, Lipkin D, Lahiri A 2006 Risk stratification in uncomplicated type 2 diabetes: prospective evaluation ofthe combined useofcoronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 27:713-721
45. Raman V, McWilliams ET, Holmberg SR, Miles K 2012 Economic analysis of the use of coronary calcium scoring as an alternative to stress ECG in the non-invasive diagnosis of coronary artery disease. Eur Radiol 22:579-587
46. Budoff MJ, Karwask YR, Ahmad IN, Nasserian C, Prat TF, Stephens J, Chang WW, Flores FR, Rizzo JA, Gunnarsson CL, McKay CR 2009 Cost-effectiveness of multidetector computed tomography compared with myocardial perfusion imaging as gatekeeper to invasive coronary angiography in asymptomatic firefighters with positive treadmill tests. J Cardiovasc Comput Tomogr 3:323-330
47. Scott-Moncrieff A, Yang J, Levine D, Taylor C, Tso D, Johnson M, Heilbron B, Leipsic J 2011 Real world estimated effective radiation doses from commonly used cardiac testing and procedural modalities. Can J Cardiol 27:613-618
48. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and innondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
49. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A 2000 Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102:1014-1019
50. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G 2000 Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153
51. 2002 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
52. 2002 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
53. Gaed EP, Lund-Anderse NH, Parving HH, Pedersen O 2008 Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591
54. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696
55. 1994 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
56. Collins R, Armitage J, Parish S, Sleigh P, Peto R 2003 MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebocontrolled trial. Lancet 361:2005-2016
57. La Rosa JC, Grundy SM, Waters DD, Shea RC, Barte RP, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435
58. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtso NM, Dad AM, Casperso NP, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS 2007 Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503-1516
59. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE 2009 A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360:2503-2515
60. 1997 Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCAinpatients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96:1761-1769
61. Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hou TB, Hugenholtz PG, Unge RF, Serruys PW 2001 Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 104:533-538
62. Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A, Angelini G, de Belder A, Oldroyd KG, Flather M, Roughton M, Nihoyannopoulos P, Bagger JP, Morgan K, Beatt KJ 2010 Randomized comparison of percutaneous coronary intervention with coronary artery bypass graftingin diabetic patients:1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 55:432-440
63. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, Cohen DJ, Mahone YE, Sleepe RL, King 3r DS, Domansk IM, McKinlay S, Fuster V 2008 Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J 155:215-223
64. 1998 Intensive blood-glucose control with sulphonylureasor insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853
65. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Got OS, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liau CS, Mas JL, Röther J, Smith Jr SC, Salette G, Contant CF, Massaro JM, Steg PG 2010 Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304:1350-1357
66. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE 2004 Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 27:1954-1961
67. Faglia E, Manuela M, Antonella Q, Michela G, Vincenzo C, Maurizio C, Roberto M, Alberto M 2005 Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am Heart J 149:e1-e6
68. Lièvre MM, Mouli NP, Thivole TC, Rodie RM, Rigallea UV, Penfornis A, Pradignac A, Ovize M 2011 Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. Trials 12:23
69. Janand-Delenn EB, Savin B, Habi BG, Bory M, Vague P, Lassmann-Vague V 1999 Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care 22:1396-1400
70. Ndrepepa G, Braun S, Schulz S, Mehilli J, Schömig A, Kastrati A 2011 High-sensitivity troponin T level and angiographic severity of coronary artery disease. Am J Cardiol 108:639-643
71. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raski NP, Zinman B 2005 Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653
72. Ford ES 2011 Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U. S.: findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 34:1337-1343